MA27658A1 - Ethers de phenoxy d'acide amine - Google Patents

Ethers de phenoxy d'acide amine

Info

Publication number
MA27658A1
MA27658A1 MA28444A MA28444A MA27658A1 MA 27658 A1 MA27658 A1 MA 27658A1 MA 28444 A MA28444 A MA 28444A MA 28444 A MA28444 A MA 28444A MA 27658 A1 MA27658 A1 MA 27658A1
Authority
MA
Morocco
Prior art keywords
amino acid
acid phenoxy
phenoxy ethers
ethers
diseases
Prior art date
Application number
MA28444A
Other languages
English (en)
Inventor
Bishwajit Nag
Abhijeet Nag
Debendranath Dey
Shiv Kumar Agarwal
Original Assignee
Bexel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bexel Pharmaceuticals Inc filed Critical Bexel Pharmaceuticals Inc
Publication of MA27658A1 publication Critical patent/MA27658A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des nouveaux éthers de phényle d'acide aminé présentant une certaine activité pour le traitement de maladies immunologiques, des inflammations, de l'obésité, de l'hyperlipidémie, de l'hypertension, des maladies neurologiques et des diabètes.
MA28444A 2003-01-17 2005-08-16 Ethers de phenoxy d'acide amine MA27658A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44077203P 2003-01-17 2003-01-17
US10/356,113 US6794401B2 (en) 2003-01-17 2003-01-31 Amino acid phenoxy ethers

Publications (1)

Publication Number Publication Date
MA27658A1 true MA27658A1 (fr) 2005-12-01

Family

ID=32716922

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28444A MA27658A1 (fr) 2003-01-17 2005-08-16 Ethers de phenoxy d'acide amine

Country Status (20)

Country Link
US (2) US6794401B2 (fr)
EP (1) EP1583529B9 (fr)
JP (1) JP4833072B2 (fr)
KR (1) KR101085315B1 (fr)
AT (1) ATE532510T1 (fr)
AU (1) AU2004207449A1 (fr)
BR (1) BRPI0406772B1 (fr)
CA (1) CA2513496C (fr)
CY (1) CY1112673T1 (fr)
DK (1) DK1583529T3 (fr)
EA (1) EA200501078A1 (fr)
ES (1) ES2374724T3 (fr)
MA (1) MA27658A1 (fr)
MX (1) MXPA05007684A (fr)
NO (1) NO330984B1 (fr)
NZ (1) NZ541328A (fr)
PT (1) PT1583529E (fr)
SI (1) SI1583529T1 (fr)
TW (1) TWI325420B (fr)
WO (1) WO2004066964A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521465B2 (en) 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
US7592486B2 (en) * 2004-09-16 2009-09-22 Board Of Regents Of The University Of Nebraska Anhydrous fluoride salts and reagents and methods for their production
US20080319031A1 (en) * 2005-03-18 2008-12-25 Orchid Chemicals & Pharmaceuticals Limited Novel Tyrosine Derivatives
US20090203744A1 (en) * 2005-07-29 2009-08-13 Pande Y Surendrakumar Satyanarayan Novel pyridine derivatives
US7989480B2 (en) 2006-08-04 2011-08-02 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors for treating inflammation
CN101784269A (zh) * 2007-06-26 2010-07-21 莱西肯医药有限公司 治疗由5-羟色胺介导的疾病和病症的方法
AU2008275179B2 (en) 2007-07-11 2013-09-12 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
WO2009030968A1 (fr) * 2007-09-05 2009-03-12 Orchid Research Laboratories Limited Inhibiteurs de mao-a ayant une sous-structure éther diphénylique
CA2721459A1 (fr) 2008-05-20 2009-11-26 Merck Sharp & Dohme Corp. Production efficace de proteines heterologues a l'aide d'inhibiteurs de la mannosyl transferase
HUE028725T2 (en) 2010-07-28 2016-12-28 Orchid Chemicals And Pharmaceuticals Ltd Diphenyl ether compounds for the treatment of liver and lung diseases, diabetes complications and cardiovascular diseases
WO2012153775A1 (fr) 2011-05-10 2012-11-15 国立大学法人神戸大学 Dérivé de thioxothiazolidine ayant un effet inhibiteur sur la fonction ras

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020049240A1 (en) * 1994-12-19 2002-04-25 Beecham Group P.1.C. Novel compounds
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
ATE185564T1 (de) * 1992-08-31 1999-10-15 Sankyo Co Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung
TW268952B (fr) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
DK0719140T3 (da) * 1993-09-15 2008-03-03 Daiichi Sankyo Co Ltd Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM
US5527546A (en) 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
DE4432101A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6004813A (en) 1995-05-11 1999-12-21 Applied Research Systems Ars Holding N.V. Il-6 activity inhibitor
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
JPH11124331A (ja) * 1997-08-21 1999-05-11 Takeda Chem Ind Ltd 抗炎症剤
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6699896B1 (en) * 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
CN1311787A (zh) * 1998-06-05 2001-09-05 阿斯特拉曾尼卡有限公司 噁唑烷酮衍生物、其制备方法以及含有它们的药物组合物
WO2000012491A1 (fr) * 1998-08-27 2000-03-09 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments dont ils sont le principe actif
DK1177187T3 (da) 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
CN1321153A (zh) 1999-07-01 2001-11-07 杰龙公司 端粒酶抑制剂及其使用方法
HUP0202520A3 (en) * 1999-08-23 2004-11-29 Kyorin Seiyaku Kk Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
JP2003508391A (ja) * 1999-08-31 2003-03-04 マキシア・ファーマシューティカルズ・インコーポレイテッド ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用
JP2001199888A (ja) * 2000-01-24 2001-07-24 Fujimoto Brothers:Kk 糖尿病治療剤
JP2001294537A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd 併用医薬
ATE310733T1 (de) 2000-04-21 2005-12-15 Pfizer Prod Inc Thyroid-rezeptorliganden
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

Also Published As

Publication number Publication date
AU2004207449A1 (en) 2004-08-12
PT1583529E (pt) 2012-02-13
US20050096366A1 (en) 2005-05-05
CA2513496A1 (fr) 2004-08-12
DK1583529T3 (da) 2012-01-23
KR20050092764A (ko) 2005-09-22
TWI325420B (en) 2010-06-01
WO2004066964A2 (fr) 2004-08-12
KR101085315B1 (ko) 2011-11-22
TW200418792A (en) 2004-10-01
NO20053714L (no) 2005-10-11
JP4833072B2 (ja) 2011-12-07
NZ541328A (en) 2008-11-28
JP2007501288A (ja) 2007-01-25
US6794401B2 (en) 2004-09-21
EP1583529A4 (fr) 2007-07-04
ES2374724T3 (es) 2012-02-21
CY1112673T1 (el) 2016-02-10
US20040142991A1 (en) 2004-07-22
EP1583529B9 (fr) 2012-04-04
EA200501078A1 (ru) 2006-02-24
ATE532510T1 (de) 2011-11-15
NO20053714D0 (no) 2005-08-01
EP1583529B1 (fr) 2011-11-09
SI1583529T1 (sl) 2012-02-29
WO2004066964A3 (fr) 2005-02-24
MXPA05007684A (es) 2006-03-10
NO330984B1 (no) 2011-08-29
BRPI0406772A (pt) 2005-12-27
EP1583529A2 (fr) 2005-10-12
WO2004066964A9 (fr) 2004-09-02
BRPI0406772B1 (pt) 2016-08-23
CA2513496C (fr) 2013-05-14

Similar Documents

Publication Publication Date Title
MA27658A1 (fr) Ethers de phenoxy d'acide amine
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
BR0307432A (pt) Difluormetiltiazolilcarboxanilidas
HK1098125A1 (en) Indane acetic acid compounds
EA200601239A1 (ru) Замещённые хинолиновые соединения
TW200509892A (en) Novel aminobenzophenone compounds
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
BRPI0413449A (pt) compostos de quinoxalina
CY1108808T1 (el) Ενωσεις μοτιλιδης
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
PT1506185E (pt) Compostos novos e sua utilizacao
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
MA30139B1 (fr) Preparation de gamma-aminoacides ayant une affinite pour la proteine alpha-2-delta.
DK1187832T3 (da) Aminoheterocycler, som er anvendelige som farmaceutiske midler
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
DE60307086D1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
PT1095059E (pt) Proteina inibidora de quimiotaxia de estafilococos (chips) e sua utilizacao
DE50303586D1 (de) Methylthiophencarboxanilide
WO2004056762A3 (fr) Nouveaux composes aminobenzophenones
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение
EA200500903A1 (ru) Силиловые простые эфиры
DE60120398D1 (de) Imidazopyridin-8-one